[go: up one dir, main page]

DK3215607T3 - Phagterapi - Google Patents

Phagterapi Download PDF

Info

Publication number
DK3215607T3
DK3215607T3 DK15794130.3T DK15794130T DK3215607T3 DK 3215607 T3 DK3215607 T3 DK 3215607T3 DK 15794130 T DK15794130 T DK 15794130T DK 3215607 T3 DK3215607 T3 DK 3215607T3
Authority
DK
Denmark
Prior art keywords
phag
therapy
phag therapy
Prior art date
Application number
DK15794130.3T
Other languages
English (en)
Inventor
Flavie Pouillot
Hélène Blois
Original Assignee
Pherecydes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherecydes Pharma filed Critical Pherecydes Pharma
Application granted granted Critical
Publication of DK3215607T3 publication Critical patent/DK3215607T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK15794130.3T 2014-11-07 2015-11-06 Phagterapi DK3215607T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306788.2A EP3018201A1 (en) 2014-11-07 2014-11-07 Phage therapy
PCT/EP2015/075949 WO2016071503A1 (en) 2014-11-07 2015-11-06 Phage therapy

Publications (1)

Publication Number Publication Date
DK3215607T3 true DK3215607T3 (da) 2022-09-05

Family

ID=51947284

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15794130.3T DK3215607T3 (da) 2014-11-07 2015-11-06 Phagterapi

Country Status (15)

Country Link
US (2) US10898530B2 (da)
EP (2) EP3018201A1 (da)
JP (1) JP6894376B2 (da)
CN (1) CN107429236A (da)
AU (1) AU2015341683B2 (da)
BR (1) BR112017009545B8 (da)
DK (1) DK3215607T3 (da)
ES (1) ES2926129T3 (da)
HU (1) HUE060113T2 (da)
IL (1) IL251976B (da)
LT (1) LT3215607T (da)
PL (1) PL3215607T3 (da)
PT (1) PT3215607T (da)
SI (1) SI3215607T1 (da)
WO (1) WO2016071503A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150955A1 (en) 2009-12-23 2011-06-23 Shannon Elizabeth Klingman Products and Methods for Reducing Malodor from the Pudendum
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
CN112203638A (zh) * 2018-01-02 2021-01-08 阿玛塔制药股份有限公司 用于治疗假单胞菌感染的噬菌体组合物
AU2019355036A1 (en) * 2018-10-04 2021-05-06 The Westmead Institute for Medical Research Bacteriophage treatment and reduction in inflammatory response
JP7549343B2 (ja) * 2018-12-27 2024-09-11 国立大学法人東海国立大学機構 宿主細菌特異的ナノ粒子
US12157869B2 (en) 2019-07-10 2024-12-03 Jeffrey Dean Lindsay Methods and compositions for reducing persistent odor in clothing and mitigating biofilms on various materials
AU2021263735A1 (en) * 2020-04-27 2022-10-27 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
US20240173369A1 (en) * 2021-03-30 2024-05-30 Biomx Ltd. Pseudomonas bacteriophage and uses thereof
US20250134802A1 (en) * 2021-09-16 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University Bacteriophages for Protection from Ultraviolet Irradiation
CN119137264A (zh) 2022-03-31 2024-12-13 株式会社钟化 黄单胞菌属细菌溶菌性噬菌体
EP4265263A1 (en) * 2022-04-19 2023-10-25 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Bacteriophage suitable for treating a bacterial infection caused by pseudomonas aeruginosa
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417188A1 (en) 2000-07-25 2002-01-31 Carl R. Merril Bacteriophage having multiple host range
WO2009075884A1 (en) 2007-12-12 2009-06-18 Intralytix, Inc. Novel e. coli bacteriophages and uses thereof
ES2703629T3 (es) * 2010-09-17 2019-03-11 Tecnifar Ind Tecnica Farmaceutica S A Fago antibacteriano, péptidos de fago y métodos de uso de los mismos
CN102199576B (zh) * 2010-11-23 2012-09-19 天津科技大学 降解铜绿假单胞菌生物被膜噬菌体的分离与筛选方法
EP2465926A1 (en) 2010-12-20 2012-06-20 University College Cork Pseudomonas aeruginosa Bacteriophage and uses thereof
CN104140957B (zh) * 2013-05-07 2017-04-26 兰州大学 一株可裂解多重耐药铜绿假单胞菌的噬菌体及其治疗感染的应用
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy

Also Published As

Publication number Publication date
US20210228659A1 (en) 2021-07-29
AU2015341683A1 (en) 2017-05-18
PT3215607T (pt) 2022-09-16
JP2017534684A (ja) 2017-11-24
CA2966944A1 (en) 2016-05-12
IL251976A0 (en) 2017-06-29
AU2015341683B2 (en) 2021-12-02
IL251976B (en) 2020-02-27
BR112017009545B1 (pt) 2024-01-02
WO2016071503A1 (en) 2016-05-12
EP3215607A1 (en) 2017-09-13
CN107429236A (zh) 2017-12-01
ES2926129T3 (es) 2022-10-24
EP3018201A1 (en) 2016-05-11
BR112017009545A2 (pt) 2018-02-14
US11779617B2 (en) 2023-10-10
WO2016071503A8 (en) 2017-06-29
PL3215607T3 (pl) 2022-11-07
HUE060113T2 (hu) 2023-01-28
SI3215607T1 (sl) 2022-11-30
US10898530B2 (en) 2021-01-26
JP6894376B2 (ja) 2021-06-30
US20170319637A1 (en) 2017-11-09
LT3215607T (lt) 2022-11-10
BR112017009545B8 (pt) 2024-01-23
EP3215607B1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
EP3463464A4 (en) ASSOCIATION TREATMENT
DK3240801T3 (da) Kombinationstumorimmunterapi
DK3209778T3 (da) Kombination
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK4242916T3 (da) Forstøver
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
FR3019458B1 (fr) Refracteur
DK3171891T3 (da) Fremgangsmåde
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3215607T3 (da) Phagterapi
DK3119396T3 (da) Muscarinreceptoragonister
DK3231444T3 (da) Ny behandling
DE102015102730B8 (de) Verbinder
EP3230438C0 (en) N-GLYCOSYLATION
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
DE112015005041A5 (de) Gargerätevorrichtung
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
FR3030184B1 (fr) Derouleuse-pailleuse